title: Monocyte chemoattractant protein-1 mediates angiotensin II-induced vascular smooth muscle cell proliferation via SAPK/JNK and ERK1/2.
abstract: Abnormal vascular smooth muscle cells proliferation is the pathophysiological basis of cardiovascular diseases, such as hypertension, atherosclerosis, and restenosis after angioplasty. Angiotensin II can induce abnormal proliferation of vascular smooth muscle cells, but the molecular mechanisms of this process remain unclear. Here, we explored the role and molecular mechanism of monocyte chemotactic protein-1, which mediated angiotensin II-induced proliferation of rat aortic smooth muscle cells. 1,000 nM angiotensin II could stimulate rat aortic smooth muscle cells' proliferation by angiotensin II type 1 receptor (AT(1)R). Simultaneously, angiotensin II increased monocyte chemotactic protein-1 expression and secretion in a dose-and time-dependent manner through activation of its receptor AT(1)R. Then, monocyte chemotactic protein-1 contributed to angiotensin II-induced cells proliferation by CCR2. Furthermore, we found that intracellular ERK and JNK signaling molecules were implicated in angiotensin II-stimulated monocyte chemotactic protein-1 expression and proliferation mediated by monocyte chemotactic protein-1. These results contribute to a better understanding effect on angiotensin II-induced proliferation of rat smooth muscle cells.
authors.affiliation: Cardiac Vascular Unit, Shanghai First People's Hospital Affiliated to Shanghai Jiao-Tong University, Shanghai 200080, China.
authors.forename: Hua-Li
authors.initials: HL
authors.lastname: Yao
authors.forename: Feng-Hou
authors.initials: FH
authors.lastname: Gao
authors.forename: Zong-Zhuang
authors.initials: ZZ
authors.lastname: Li
authors.forename: Hong-Xian
authors.initials: HX
authors.lastname: Wu
authors.forename: Meng-Dan
authors.initials: MD
authors.lastname: Xu
authors.forename: Zhi
authors.initials: Z
authors.lastname: Zhang
authors.forename: Qiu-Yan
authors.initials: QY
authors.lastname: Dai
mesh_terms: D000804:Angiotensin II / Q000502:physiology*; D000818:Animals; D000873:Anthracenes / Q000494:pharmacology; D001013:Aorta, Thoracic / Q000166:cytology; D048588:Benzoxazines / Q000494:pharmacology; D002070:Butadienes / Q000494:pharmacology; D049109:Cell Proliferation; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000235:genetics / Q000378:metabolism*; D020935:MAP Kinase Signaling System; D008297:Male; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000166:cytology*; D032389:Myocytes, Smooth Muscle / Q000378:metabolism / Q000502:physiology*; D009570:Nitriles / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism; D054390:Receptors, CCR2 / Q000037:antagonists & inhibitors
chemical_list: D000873:Anthracenes; D048588:Benzoxazines; D002070:Butadienes; C491766:Ccl2 protein, rat; D018932:Chemokine CCL2; D009570:Nitriles; D010880:Piperidines; C573791:RS 102895; D044140:Receptor, Angiotensin, Type 1; D054390:Receptors, CCR2; C113580:U 0126; D000804:Angiotensin II; C432165:pyrazolanthrone; D020928:Mitogen-Activated Protein Kinases